Evidence map›Paper›PMID 41281753›Full record

ArticleInternational journal of biological sciences2025

Synergistic Anti-Tumor Effects of Sulfatinib and Kaempferol on Pancreatic Neuroendocrine Tumors via CALCA-mediated PI3K/AKT/mTOR Pathway.

Lingyi Chen, Pengfei Liu, Fengjuan Chen, Bingyan Xue, Xu Han, Lijun Yan, Jianan Bai, Xiaoya Li, Min Liu, Ye Tian and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of biological sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Lingyi ChenDepartment of Neuroendocrine Tumor, The First Affiliated Hospital with Nanjing Medical University, Jiangsu, China.
Pengfei LiuDepartment of Gastroenterology, Jiangyin People's Hospital, Jiangsu, China.
Fengjuan ChenDepartment of Gastroenterology, Xishan People's Hospital, Jiangsu, China.
Bingyan XueDepartment of Neuroendocrine Tumor, The First Affiliated Hospital with Nanjing Medical University, Jiangsu, China.
Xu HanDepartment of Neuroendocrine Tumor, The First Affiliated Hospital with Nanjing Medical University, Jiangsu, China.
Lijun YanDepartment of Neuroendocrine Tumor, The First Affiliated Hospital with Nanjing Medical University, Jiangsu, China.
Jianan BaiDepartment of Neuroendocrine Tumor, The First Affiliated Hospital with Nanjing Medical University, Jiangsu, China.
Xiaoya LiDepartment of Neuroendocrine Tumor, The First Affiliated Hospital with Nanjing Medical University, Jiangsu, China.
Min LiuDepartment of Neuroendocrine Tumor, The First Affiliated Hospital with Nanjing Medical University, Jiangsu, China.
Ye TianDepartment of Neuroendocrine Tumor, The First Affiliated Hospital with Nanjing Medical University, Jiangsu, China.
Mujie YeDepartment of Neuroendocrine Tumor, The First Affiliated Hospital with Nanjing Medical University, Jiangsu, China.
Qiyun TangDepartment of Neuroendocrine Tumor, The First Affiliated Hospital with Nanjing Medical University, Jiangsu, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pancreatic neuroendocrine tumors (pNETs) represent a diverse category of neoplasms originating from pancreatic neuroendocrine cells. Although these tumors generally exhibit a relatively indolent nature, they often metastasize early in their course, significantly affecting patient outcomes. Sulfatinib (SULF) is associated with considerable toxicity and resistance challenges, leading to many patients failing to achieve long-term disease management. In contrast, Kaempferol (KMP), a naturally occurring phytochemical, has shown considerable promise in anti-tumor treatments. Our study revealed that the combination of SULF and low-dose KMP enhances the sensitivity of pNET cells to SULF. Moreover, this combination demonstrated a synergistic effect on angiogenesis inhibition, observed in both

Indexed as

KaempferolsNeuroendocrine TumorsPancreatic NeoplasmsAnimalsAntineoplastic AgentsCell Line, TumorCell ProliferationDrug SynergismHumansMiceMice, NudePhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktSignal TransductionTOR Serine-Threonine KinasesXenograft Model Antitumor AssaysAntineoplastic AgentskaempferolKaempferolsPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktTOR Serine-Threonine Kinaseskaempferolpancreatic neuroendocrine tumorspharmacotherapysulfatinib

Identifiers

PMID41281753
PMCPMC12631220

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.